Inhibitors of Angiogenesis: Design, Synthesis and Biological Exploitation
Public support
Provider
Ministry of Education, Youth and Sports
Programme
COST
Call for proposals
COST 6 (SMSM2008OC3)
Main participants
—
Contest type
VS - Public tender
Contract ID
1146/2010-32
Alternative language
Project name in Czech
Silybin a jeho deriváty jako účinné anti angiogenní a chemoprotektivní látky
Annotation in Czech
Příprava konjugátů silybinu s mastnými a fenolovými kyselinami pomocí chemických a enzymových metod s cílem přípravy účinných antiangiogenních a chemoprotektivních preparátů
Scientific branches
R&D category
ZV - Basic research
CEP classification - main branch
CC - Organic chemistry
CEP - secondary branch
CE - Biochemistry
CEP - another secondary branch
FD - Oncology and haematology
OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)
10401 - Organic chemistry<br>10608 - Biochemistry and molecular biology<br>10609 - Biochemical research methods<br>30204 - Oncology<br>30205 - Hematology
Completed project evaluation
Provider evaluation
V - Vynikající výsledky projektu (s mezinárodním významem atd.)
Project results evaluation
Newly prepared silybin fatty acid conjugates proved to be active against influenza virus without substantial cyctotoxicity. These conjugates were used for the silybin A and B separation using lipases. Series of silybin A and B and dehydrosilybin galloylderivatives was tested for antiangiogenic activity. The highest activity (HUVEC proliferation inhibition) has 7-O-galloylsilybin.
Solution timeline
Realization period - beginning
Jan 1, 2008
Realization period - end
Jun 30, 2011
Project status
U - Finished project
Latest support payment
Feb 22, 2011
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP12-MSM-OC-U/01:1
Data delivery date
Jul 12, 2012
Finance
Total approved costs
1,553 thou. CZK
Public financial support
1,553 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
0 thou. CZK